Market Overview

FDA Approves NDA for Teva's Quartette Tablets to Prevent Pregnancy

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today announced that
the U.S. Food and Drug Administration (FDA) has approved Quartette™
(levonorgestrel/ethinyl estradiol and ethinyl estradiol) tablets for the
prevention of pregnancy. Quartette™ represents the next generation of
extended regimen oral contraceptives to be approved by the FDA, and was
designed to minimize breakthrough bleeding (BTB) between scheduled
periods. The approval of Quartette™ demonstrates Teva's continued
commitment to the development and production of an innovative range of
pharmaceutical products that support the health of women around the
world.

“Breakthrough bleeding can be experienced with any birth control pill,
especially during the first few months, and is one of the reasons a
large

See full press release

Posted-In: News Guidance

 

Related Articles (TEVA)

Around the Web, We're Loving...

Get Benzinga's Newsletters